Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Adeno Associated Virus Aav Vector Based Gene Therapy Market

ID: MRFR/HC/27946-HCR
128 Pages
Nidhi Mandole
Last Updated: April 06, 2026

Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Research Report: Size, Share, Trend Analysis By Disease Type (Hematological Malignancies, Neurological Disorders, Cardiovascular Diseases, Ophthalmic Diseases, Oncology), By Vector Serotype (AAV1, AAV2, AAV5, AAV6, AAV8, AAV9), By Administration Route (Intravenous, Intramuscular, Subcutaneous, Intraocular, Intracerebral) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Adeno Associated Virus Aav Vector Based Gene Therapy Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Disease Type (USD Billion)
  49.     4.1.1 Hematological Malignancies
  50.     4.1.2 Neurological Disorders
  51.     4.1.3 Cardiovascular Diseases
  52.     4.1.4 Ophthalmic Diseases
  53.     4.1.5 Oncology
  54.   4.2 Healthcare, BY Vector Serotype (USD Billion)
  55.     4.2.1 AAV1
  56.     4.2.2 AAV2
  57.     4.2.3 AAV5
  58.     4.2.4 AAV6
  59.     4.2.5 AAV8
  60.     4.2.6 AAV9
  61.   4.3 Healthcare, BY Administration Route (USD Billion)
  62.     4.3.1 Intravenous
  63.     4.3.2 Intramuscular
  64.     4.3.3 Subcutaneous
  65.     4.3.4 Intraocular
  66.     4.3.5 Intracerebral
  67.   4.4 Healthcare, BY Region (USD Billion)
  68.     4.4.1 North America
  69.       4.4.1.1 US
  70.       4.4.1.2 Canada
  71.     4.4.2 Europe
  72.       4.4.2.1 Germany
  73.       4.4.2.2 UK
  74.       4.4.2.3 France
  75.       4.4.2.4 Russia
  76.       4.4.2.5 Italy
  77.       4.4.2.6 Spain
  78.       4.4.2.7 Rest of Europe
  79.     4.4.3 APAC
  80.       4.4.3.1 China
  81.       4.4.3.2 India
  82.       4.4.3.3 Japan
  83.       4.4.3.4 South Korea
  84.       4.4.3.5 Malaysia
  85.       4.4.3.6 Thailand
  86.       4.4.3.7 Indonesia
  87.       4.4.3.8 Rest of APAC
  88.     4.4.4 South America
  89.       4.4.4.1 Brazil
  90.       4.4.4.2 Mexico
  91.       4.4.4.3 Argentina
  92.       4.4.4.4 Rest of South America
  93.     4.4.5 MEA
  94.       4.4.5.1 GCC Countries
  95.       4.4.5.2 South Africa
  96.       4.4.5.3 Rest of MEA
  97. 5 SECTION V: COMPETITIVE ANALYSIS
  98.   5.1 Competitive Landscape
  99.     5.1.1 Overview
  100.     5.1.2 Competitive Analysis
  101.     5.1.3 Market share Analysis
  102.     5.1.4 Major Growth Strategy in the Healthcare
  103.     5.1.5 Competitive Benchmarking
  104.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  105.     5.1.7 Key developments and growth strategies
  106.       5.1.7.1 New Product Launch/Service Deployment
  107.       5.1.7.2 Merger & Acquisitions
  108.       5.1.7.3 Joint Ventures
  109.     5.1.8 Major Players Financial Matrix
  110.       5.1.8.1 Sales and Operating Income
  111.       5.1.8.2 Major Players R&D Expenditure. 2023
  112.   5.2 Company Profiles
  113.     5.2.1 Spark Therapeutics (US)
  114.       5.2.1.1 Financial Overview
  115.       5.2.1.2 Products Offered
  116.       5.2.1.3 Key Developments
  117.       5.2.1.4 SWOT Analysis
  118.       5.2.1.5 Key Strategies
  119.     5.2.2 Bayer AG (DE)
  120.       5.2.2.1 Financial Overview
  121.       5.2.2.2 Products Offered
  122.       5.2.2.3 Key Developments
  123.       5.2.2.4 SWOT Analysis
  124.       5.2.2.5 Key Strategies
  125.     5.2.3 Novartis AG (CH)
  126.       5.2.3.1 Financial Overview
  127.       5.2.3.2 Products Offered
  128.       5.2.3.3 Key Developments
  129.       5.2.3.4 SWOT Analysis
  130.       5.2.3.5 Key Strategies
  131.     5.2.4 Bristol-Myers Squibb (US)
  132.       5.2.4.1 Financial Overview
  133.       5.2.4.2 Products Offered
  134.       5.2.4.3 Key Developments
  135.       5.2.4.4 SWOT Analysis
  136.       5.2.4.5 Key Strategies
  137.     5.2.5 GSK (GB)
  138.       5.2.5.1 Financial Overview
  139.       5.2.5.2 Products Offered
  140.       5.2.5.3 Key Developments
  141.       5.2.5.4 SWOT Analysis
  142.       5.2.5.5 Key Strategies
  143.     5.2.6 Pfizer Inc. (US)
  144.       5.2.6.1 Financial Overview
  145.       5.2.6.2 Products Offered
  146.       5.2.6.3 Key Developments
  147.       5.2.6.4 SWOT Analysis
  148.       5.2.6.5 Key Strategies
  149.     5.2.7 Sarepta Therapeutics (US)
  150.       5.2.7.1 Financial Overview
  151.       5.2.7.2 Products Offered
  152.       5.2.7.3 Key Developments
  153.       5.2.7.4 SWOT Analysis
  154.       5.2.7.5 Key Strategies
  155.     5.2.8 Astellas Pharma Inc. (JP)
  156.       5.2.8.1 Financial Overview
  157.       5.2.8.2 Products Offered
  158.       5.2.8.3 Key Developments
  159.       5.2.8.4 SWOT Analysis
  160.       5.2.8.5 Key Strategies
  161.     5.2.9 UniQure N.V. (NL)
  162.       5.2.9.1 Financial Overview
  163.       5.2.9.2 Products Offered
  164.       5.2.9.3 Key Developments
  165.       5.2.9.4 SWOT Analysis
  166.       5.2.9.5 Key Strategies
  167.   5.3 Appendix
  168.     5.3.1 References
  169.     5.3.2 Related Reports
  170. 6 LIST OF FIGURES
  171.   6.1 MARKET SYNOPSIS
  172.   6.2 NORTH AMERICA MARKET ANALYSIS
  173.   6.3 US MARKET ANALYSIS BY DISEASE TYPE
  174.   6.4 US MARKET ANALYSIS BY VECTOR SEROTYPE
  175.   6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
  176.   6.6 CANADA MARKET ANALYSIS BY DISEASE TYPE
  177.   6.7 CANADA MARKET ANALYSIS BY VECTOR SEROTYPE
  178.   6.8 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  179.   6.9 EUROPE MARKET ANALYSIS
  180.   6.10 GERMANY MARKET ANALYSIS BY DISEASE TYPE
  181.   6.11 GERMANY MARKET ANALYSIS BY VECTOR SEROTYPE
  182.   6.12 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
  183.   6.13 UK MARKET ANALYSIS BY DISEASE TYPE
  184.   6.14 UK MARKET ANALYSIS BY VECTOR SEROTYPE
  185.   6.15 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
  186.   6.16 FRANCE MARKET ANALYSIS BY DISEASE TYPE
  187.   6.17 FRANCE MARKET ANALYSIS BY VECTOR SEROTYPE
  188.   6.18 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
  189.   6.19 RUSSIA MARKET ANALYSIS BY DISEASE TYPE
  190.   6.20 RUSSIA MARKET ANALYSIS BY VECTOR SEROTYPE
  191.   6.21 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  192.   6.22 ITALY MARKET ANALYSIS BY DISEASE TYPE
  193.   6.23 ITALY MARKET ANALYSIS BY VECTOR SEROTYPE
  194.   6.24 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
  195.   6.25 SPAIN MARKET ANALYSIS BY DISEASE TYPE
  196.   6.26 SPAIN MARKET ANALYSIS BY VECTOR SEROTYPE
  197.   6.27 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
  198.   6.28 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE
  199.   6.29 REST OF EUROPE MARKET ANALYSIS BY VECTOR SEROTYPE
  200.   6.30 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
  201.   6.31 APAC MARKET ANALYSIS
  202.   6.32 CHINA MARKET ANALYSIS BY DISEASE TYPE
  203.   6.33 CHINA MARKET ANALYSIS BY VECTOR SEROTYPE
  204.   6.34 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  205.   6.35 INDIA MARKET ANALYSIS BY DISEASE TYPE
  206.   6.36 INDIA MARKET ANALYSIS BY VECTOR SEROTYPE
  207.   6.37 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  208.   6.38 JAPAN MARKET ANALYSIS BY DISEASE TYPE
  209.   6.39 JAPAN MARKET ANALYSIS BY VECTOR SEROTYPE
  210.   6.40 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
  211.   6.41 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE
  212.   6.42 SOUTH KOREA MARKET ANALYSIS BY VECTOR SEROTYPE
  213.   6.43 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  214.   6.44 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE
  215.   6.45 MALAYSIA MARKET ANALYSIS BY VECTOR SEROTYPE
  216.   6.46 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  217.   6.47 THAILAND MARKET ANALYSIS BY DISEASE TYPE
  218.   6.48 THAILAND MARKET ANALYSIS BY VECTOR SEROTYPE
  219.   6.49 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
  220.   6.50 INDONESIA MARKET ANALYSIS BY DISEASE TYPE
  221.   6.51 INDONESIA MARKET ANALYSIS BY VECTOR SEROTYPE
  222.   6.52 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  223.   6.53 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE
  224.   6.54 REST OF APAC MARKET ANALYSIS BY VECTOR SEROTYPE
  225.   6.55 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
  226.   6.56 SOUTH AMERICA MARKET ANALYSIS
  227.   6.57 BRAZIL MARKET ANALYSIS BY DISEASE TYPE
  228.   6.58 BRAZIL MARKET ANALYSIS BY VECTOR SEROTYPE
  229.   6.59 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
  230.   6.60 MEXICO MARKET ANALYSIS BY DISEASE TYPE
  231.   6.61 MEXICO MARKET ANALYSIS BY VECTOR SEROTYPE
  232.   6.62 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
  233.   6.63 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE
  234.   6.64 ARGENTINA MARKET ANALYSIS BY VECTOR SEROTYPE
  235.   6.65 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  236.   6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE
  237.   6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY VECTOR SEROTYPE
  238.   6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  239.   6.69 MEA MARKET ANALYSIS
  240.   6.70 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE
  241.   6.71 GCC COUNTRIES MARKET ANALYSIS BY VECTOR SEROTYPE
  242.   6.72 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
  243.   6.73 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE
  244.   6.74 SOUTH AFRICA MARKET ANALYSIS BY VECTOR SEROTYPE
  245.   6.75 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  246.   6.76 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE
  247.   6.77 REST OF MEA MARKET ANALYSIS BY VECTOR SEROTYPE
  248.   6.78 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  249.   6.79 KEY BUYING CRITERIA OF HEALTHCARE
  250.   6.80 RESEARCH PROCESS OF MRFR
  251.   6.81 DRO ANALYSIS OF HEALTHCARE
  252.   6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  253.   6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  254.   6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
  255.   6.85 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE)
  256.   6.86 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion)
  257.   6.87 HEALTHCARE, BY VECTOR SEROTYPE, 2024 (% SHARE)
  258.   6.88 HEALTHCARE, BY VECTOR SEROTYPE, 2024 TO 2035 (USD Billion)
  259.   6.89 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
  260.   6.90 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
  261.   6.91 BENCHMARKING OF MAJOR COMPETITORS
  262. 7 LIST OF TABLES
  263.   7.1 LIST OF ASSUMPTIONS
  264.     7.1.1
  265.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  266.     7.2.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  267.     7.2.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  268.     7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  269.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  270.     7.3.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  271.     7.3.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  272.     7.3.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  273.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  274.     7.4.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  275.     7.4.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  276.     7.4.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  277.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  278.     7.5.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  279.     7.5.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  280.     7.5.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  281.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  282.     7.6.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  283.     7.6.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  284.     7.6.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  285.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  286.     7.7.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  287.     7.7.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  288.     7.7.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  289.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  290.     7.8.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  291.     7.8.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  292.     7.8.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  293.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  294.     7.9.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  295.     7.9.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  296.     7.9.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  297.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  298.     7.10.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  299.     7.10.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  300.     7.10.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  301.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  302.     7.11.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  303.     7.11.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  304.     7.11.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  305.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  306.     7.12.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  307.     7.12.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  308.     7.12.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  309.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  310.     7.13.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  311.     7.13.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  312.     7.13.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  313.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  314.     7.14.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  315.     7.14.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  316.     7.14.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  317.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  318.     7.15.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  319.     7.15.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  320.     7.15.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  321.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  322.     7.16.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  323.     7.16.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  324.     7.16.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  325.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  326.     7.17.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  327.     7.17.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  328.     7.17.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  329.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  330.     7.18.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  331.     7.18.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  332.     7.18.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  333.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  334.     7.19.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  335.     7.19.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  336.     7.19.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  337.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  338.     7.20.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  339.     7.20.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  340.     7.20.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  341.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  342.     7.21.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  343.     7.21.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  344.     7.21.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  345.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  346.     7.22.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  347.     7.22.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  348.     7.22.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  349.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  350.     7.23.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  351.     7.23.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  352.     7.23.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  353.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  354.     7.24.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  355.     7.24.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  356.     7.24.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  357.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  358.     7.25.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  359.     7.25.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  360.     7.25.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  361.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  362.     7.26.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  363.     7.26.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  364.     7.26.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  365.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  366.     7.27.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  367.     7.27.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  368.     7.27.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  369.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  370.     7.28.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  371.     7.28.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  372.     7.28.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  373.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  374.     7.29.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  375.     7.29.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  376.     7.29.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  377.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  378.     7.30.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  379.     7.30.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  380.     7.30.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  381.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  382.     7.31.1
  383.   7.32 ACQUISITION/PARTNERSHIP
  384.     7.32.1

Healthcare Market Segmentation

Healthcare By Disease Type (USD Billion, 2025-2035)

  • Hematological Malignancies
  • Neurological Disorders
  • Cardiovascular Diseases
  • Ophthalmic Diseases
  • Oncology

Healthcare By Vector Serotype (USD Billion, 2025-2035)

  • AAV1
  • AAV2
  • AAV5
  • AAV6
  • AAV8
  • AAV9

Healthcare By Administration Route (USD Billion, 2025-2035)

  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Intraocular
  • Intracerebral

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions